News

Income from operations was $12.8m for the full year ended 30 June 2010, compared to $10m for the year ago period. For the full year ended 30 June

The increase in sales revenue resulted from the increase of the company’s sales volume and selling prices. Net profit for fiscal 2010 was $3.2m or 0.17 per share

Medtronic’s IN.PACT drug-eluting balloons feature a hydrophilic coating called FreePac that frees and separates paclitaxel molecules, facilitating their absorption into the vessel wall to mitigate re-narrowing of the

The company has posted a net loss of $413,864 for the year ended 30 June 2010, or $ 0.06 loss per diluted share, compared to net loss of

Apligraf is a living cell based product used by physicians to heal chronic wounds in patients in the US and around the world. Apligraf contains two layers of

As per the terms of the collaboration, BAC developed CaptureSelect custom affinity ligands for use in monitoring Genmab UniBody drug candidates in preclinical studies and clinical trials, and

APS001 is a new anticancer agent currently under development at Anaeropharma Science that utilises characteristic features of Bifidobacterium longum. Eisai’s both contracts cover the development of drugs that

Most recently, Forster was the CEO of Solace Pharmaceuticals. Before joining Solace Pharma, Forster was the head of EU Development and of Development Operations in the EU &

Cevec Pharma also added that the virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine